Therapeutic Effect of Green Seaweed Against Metabloc Syndrome
NCT ID: NCT05786534
Last Updated: 2023-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2022-12-09
2023-11-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of MD on MetS Patients
NCT06961682
Mobile Health (M-health) Intervention to Reduce the Epigenetic Signature in Metabolic Syndrome (MetS)
NCT06448806
Effect of a Low Glycemic Index on Metabolic Syndrome
NCT02356952
The Effect of Mastiha Oil in Metabolic Syndrome
NCT04785573
Impact of Extra Virgin Olive Oil (EVOO) with Health Properties in Metabolic Syndrome
NCT05282316
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Statement of problem: The number of people with high LDL-cholesterol, body mass index and fasting plasma glucose levels has been increasing. These factors are promoting the risk of metabolic syndrome in Pakistan. 26-38% people in Pakistan are reported to be a patient of metabolic syndrome. Seaweed has shown to be protective against the syndrome in previous studies. The goal of this study is to check the role of green seaweed against metabolic syndrome.
Hypothesis: Green seaweed (Ulva Lactuca) has a potential to manage metabolic syndrome.
Objective: To assess the therapeutic effect of green seaweed (Ulva Lactuca) against metabolic syndrome.
Methodology: Green seaweed powder will be procured from Taokaenoi Food and Marketing Public Co., Ltd. (Thailand). The proximate analysis of the product will be performed and then capsules of powder will be prepared to be consumed by the participants. Total 40 subjects (20 in treatment group and 20 in control group) will be selected and green seaweed powder will be added in their diets (200mg twice a day). After a trial of 40 days, the patients will be assessed. Assessment will include anthropometric measurements, blood pressure, lipid profile analysis and total antioxidant capacity (TAC) which will be monitored before and after the trial and final,ly, the data collected will be analyzed by using SPSS 25 by paired sample t test. P value ≤ 0.05 will be considered significant.
Expected outcomes: Green seaweed (Ulva Lactuca) powder will prove to have therapeutic potential against obesity, hypertension, glucose intolerance and dyslipidemia.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metabolic Syndrome patients
Green seaweed Ulva Lactuca is used for preventing symptoms in Metabolic Syndrome patients
Green Seaweed
400 mg per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Green Seaweed
400 mg per day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Dyslipidemia
* Altered blood glucose level
* Age 30-55 ( male and female)
Exclusion Criteria
* Liver disease
* Kidney disorder
* Cancer etc
35 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Veterinary and Animal Sciences, Lahore - Pakistan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Asif Ali
Researcher
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ashraf Hospital
Chak One Hundred Seventy-five Nine Left, Punjab Province, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cardoso SM, Pereira OR, Seca AM, Pinto DC, Silva AM. Seaweeds as Preventive Agents for Cardiovascular Diseases: From Nutrients to Functional Foods. Mar Drugs. 2015 Nov 12;13(11):6838-65. doi: 10.3390/md13116838.
Related Links
Access external resources that provide additional context or updates about the study.
Seaweeds as Preventive Agents for Cardiovascular Diseases
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Green Seaweed
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.